The present disclosure relates generally to the field of inhalation devices. The disclosure has particular utility in connection with the delivery of powdered medications to a patient, and will be described in connection with such utility, although other utilities are contemplated.
Certain diseases of the respiratory tract are known to respond to treatment by the direct application of therapeutic agents. As these agents are most readily available in dry powdered form, their application is most conveniently accomplished by inhaling the powdered material through the nose or mouth. This powdered form results in the better utilization of the medicament in that the drug is deposited exactly at the site desired and where its action may be required; hence, very minute doses of the drug are often equally as efficacious as larger doses administered by other means, with a consequent marked reduction in the incidence of undesired side effects and medicament cost. Alternatively, the drug in this form may be used for treatment of diseases other than those of the respiratory system. When the drug is deposited on the very large surface areas of the lungs, it may be very rapidly absorbed into the blood stream; hence, this method of application may take the place of administration by injection, tablet, or other conventional means.
It is the opinion of the pharmaceutical industry that the bioavailability of the drug is optimum when the drug particles delivered to the respiratory tract are between 1 to 5 microns in size. When the drug particles need to be in this size range the dry powder delivery system needs to address a number of issues:
(1) Small size particles may develop an electrostatic charge on themselves during manufacturing and storage. This may cause the particles to agglomerate or aggregate, resulting in clusters of particles which have an effective size greater than 5 microns. The probability of these large clusters making it to the deep lungs then decreases. This in turn results in a lower percentage of the packaged drug being available to the patient for absorption.
(2) The amount of active drug that needs to be delivered to the patient may be of the order of 10 s of micrograms. For example, in the case of albuterol, a drug used in asthma, this is usually 25 to 50 micrograms. Current manufacturing equipment can effectively deliver aliquots of drugs in milligram dose range with acceptable accuracy. So the standard practice is to mix the active drug with a filler or bulking agent such as lactose. This additive also makes the drug “easy to flow”. This filler is also called a carrier since the drug particles also stick to these particles through electrostatic or chemical bonds. These carrier particles are very much larger than the drug particles in size. The ability of the dry powder inhaler to separate drug from the carrier is an important performance parameter in the effectiveness of the design.
(3) Active drug particles with sizes greater than 5 microns will be deposited either in the mouth or throat. This introduces another level of uncertainty since the bioavailability and absorption of the drug in these locations is different from the lungs. Dry powder inhalers need to minimize the drug deposited in these locations to reduce the uncertainty associated with the bioavailability of the drug.
Prior art dry powder inhalers (DPIs) usually have a means for introducing the drug (active drug plus carrier) into a high velocity air stream. The high velocity air stream is used as the primary mechanism for breaking up the cluster of micronized particles or separating the drug particles from the carrier. Several inhalation devices useful for dispensing this powder form of medicament are known in the prior art. For example, in U.S. Pat. Nos. 3,507,277; 3,518,992; 3,635,219; 3,795,244; and 3,807,400, inhalation devices are disclosed having means for piercing of a capsule containing a powdered medicament, which upon inhalation is drawn out of the pierced capsule and into the user's mouth. Several of these patents disclose propeller means, which upon inhalation aid in dispensing the powder out of the capsule, so that it is not necessary to rely solely on the inhaled air to suction powder from the capsule. For example, in U.S. Pat. No. 2,517,482, a device is disclosed having a powder containing capsule placed in a lower chamber before inhalation, where it is pierced by manual depression of a piercing pin by the user. After piercing, inhalation is begun and the capsule is drawn into an upper chamber of the device where it moves about in all directions to cause a dispensing of powder through the pierced holes and into the inhaled air stream. U.S. Pat. No. 3,831,606 discloses an inhalation device having multiple piercing pins, propeller means, and a self-contained power source for operating the propeller means via external manual manipulation, so that upon inhalation the propeller means aids in dispensing the powder into the stream of inhaled air. See also U.S. Pat. Nos. 3,948,264 and 5,458,135.
In prior U.S. Pat. Nos. 7,318,434 and 7,334,577 incorporated herein by reference, and assigned to the common assignee MicroDose Therapeutx, Inc., there is provided an improvement over prior art inhalers that utilize vibration to facilitate suspension of power into an inhaled gas stream and which utilizes synthetic jetting to aerosolize drug powder from a blister pack or the like. As taught in the aforesaid U.S. Pat. Nos. 7,318,434 and 7,334,577 there is provided a dry powder inhaler having a first chamber such as a blister pack or other container, for and holding a dry powder, and a second chamber connected to the first chamber via a passageway for receiving an aerosolized form of the dry powder from the first chamber and for delivering the aerosolized dry powder to a user. A vibrator is coupled to the dry powder in the first chamber. The vibrator is energized and coupled to the first chamber and drives the powder from the chamber by synthetic jetting.
As described in U.S. Pat. No. 7,080,644 also incorporated herein by reference, and also assigned to common assignee MicroDose Therapeutx, Inc., controlled aliquots or doses of a medication or drug are pre-packaged in a blister pack, which includes a frangible crowned top element which may be conical, conical with a rounded point, rounded, or other raised shape configuration, and a bottom element which may be a flat web or membrane, or which itself may be of shaped configuration, e.g. conical, round, dish shaped, etc. for closely engaging with an underlying vibrating element, the shape and size of which is chosen to provide optimum controlled delivery of a given medication or drug. The top element of the blister pack is pierced with a piercing device such as a sharp needle to form one or more apertures for delivery of the medication or drug contained within the blister pack. The hole pattern and hole size is selected to provide optimization of delivery of the particular medication or drug packaged therein.
The present disclosure provides an improvement over the prior art devices such as discussed above by providing an inhaler having a vibration element for aerosolizing medicament contained in a blister pack, wherein the inhaler is adapted to hold a plurality of individual blister packs which can be individually accessed and moved into an operative or dispensing position between the vibration element and a piercing element. The advantages of this construction include: simpler, more compact assembly for an inhaler containing a plurality of blister packs; and the ability to isolate and shield individual blister packs from the piercing element prior to use.
One aspect of the present disclosure provides a medication inhaler, with a housing, including a vibrating element. The housing also includes a chamber-defining flow-channel wherein a blister containing medicament is clamped in place by the chamber. The blister is also in contact with the vibrating element. The positioning is accomplished by a blister pack clamping surface, allowing three rotational degrees of freedom between the chamber and blister pack, and allowing the crown of the blister to be engaged at least in part with the chamber.
Further features and advantages of the present disclosure will be seen from the following detailed description, taken in conjunction with the accompanying drawings, wherein
a and 8b are detailed sectional views of the blister pack carrier and piercing mechanism in accordance with the present disclosure;
In the following description, reference is made to the accompanying drawings, which form a part hereof, and in which is shown, by way of illustration, various embodiments of the present disclosure. It is understood that other embodiments may be utilized and changes may be made without departing from the scope of the present disclosure.
The present disclosure provides a device for delivering medicament to the airway of a user, wherein the device generally comprises a housing with a mouthpiece affixed and a cover for the mouthpiece. The housing is adapted to hold a plurality of individual blister packs containing, for example, powdered medicament. However, the medication could be a liquid form medication. The blisters are arranged such that individual blisters may be loaded into a clamping position, whereupon the blister is pierced and a vibrating device is used to aggregate the contents of the blister, which is subsequently inhaled by the user. Preferably the blisters are carried in a cartridge which in a preferred form comprises a rotary cassette containing a plurality of individually addressable blister packs. The device also includes a mechanism for moving selected blister packs between a stowed position and an operative position. The mechanism may also be used to activate the piercing and vibrating elements.
Referring to
Referring to
The distal end of the lever arm (relative to the cam disk) forms a button area 11A that is configured to allow a user to easily grip and move the lever arm. For example, the surface area of the button should be large enough to allow easy pulling of the lever arm and the surface of the button may also be comprised of a material that enhances the grip of the user. At either end of the motion of the lever arm, the device may include a sequence lock that allows the lever arm and cam disk to remain in a fixed position until the user moves the lever arm again.
Alternatively, other motions may be used to activate the device. For example, the cover of the device may be connected to the cam disk by a linkage that turns the cam disk when the cover is opened.
Referring to
As shown in
As described above, the medicament or drug contained in the blister pack is delivered to the patient by pushing a fresh blister pack 21 into position using blister carrier 27. The motion of the blister carrier is in a radial direction, as indicated by the arrows in
Motion of the blister carrier, as well as the retractable cover is initiated by the movement of the lever arm 11, the rotational motion of which is transferred to other respective elements using cam disk 10, which includes a series of slots, cams, and/or pins that control the movement of linkages connected to other elements of the device. These connections are demonstrated by
Where cams, slots and follower pins, rotating pins, or other pieces conflict with one another, the cam disk 10 may comprise of two flat inner and outer disks joined together, such as for example, being joined at a hub. In this manner, the disk may include overlapping slots or cams.
Referring to
The piercing assembly is aligned with the blister pack on the opposite side of the flow channel with the piercer 51 extending through holes 32 when used to puncture the blister pack. The piercer may comprise a needle or plurality of needles to adequately puncture the blister pack.
The vibrating assembly 40 may include a piezoelectric transducer 41 as a vibrating element, but other vibrating elements are also within the scope of the present disclosure, such for example as a microphone providing a sonic vibration. The vibrating element causes the powdered medicament within the blister pack to be aerosolized in the surrounding air and may create a synthetic jet that distributes the medicament into the flow channel 30. The medicament is then transported into the patient's inhalation air stream drawn through the mouthpiece 2.
The vibrating element may be activated by flow sensor 60 which senses the breath of the patient as described in U.S. Pat. No. 6,152,130 and in co-pending U.S. application Ser. No. 11/064, 201, both of which are commonly owned and are incorporated herein by reference. Referring to
Once a blister pack has been emptied, it may be disposed of by extracting the empty blister through the top of the housing next to the mouthpiece 2. Alternatively, it may be stored in the cartridge or otherwise out of the way until all the blister packs are depleted, at which time a fresh cassette may be loaded into the inhaler after the emptied cassette is removed.
Another aspect of the present disclosure provides an improved device for positioning and clamping a blister in connection with a vibrating element.
An alternative and preferred clamping mechanism, which significantly improves the powder deagglomeration and consistency of delivery of dry powder inhalers utilizing vibratory elements, is shown in
Also, with this arrangement, by making contact with the upper wall of the first chamber, vibratory energy for the formation of the synthetic jet is preserved, thereby eliminating any damping that may otherwise result.
To test this feature, identical dry powder inhalers were produced which differed only in the mechanism for clamping the first chamber by the second chamber, e.g. bottom vs. top clamping and were evaluated with the same dry powder and operating conditions; the results demonstrated significant improvement of the top clamp over the bottom clamp in the following measures of performance:
1) Improved consistency of engagement of the first chamber to the piezoelectric element.
2) Lower damping as measured by higher average piezoelectric frequency and lower impedance.
3) Higher peak entrained airspeed of the synthetic jet,
4) Lower first chamber movement, likely preventing shifts in mode of vibration.
5) Higher average aerosol performance and lower variability.
It should be emphasized that the above-described embodiments of the present device and process, particularly, and “preferred” embodiments, are merely possible examples of implementations and merely set forth for a clear understanding of the principles of the disclosure. Many different embodiments of the method and device for clamping a blister within a dry powder inhaler described herein may be designed and/or fabricated without departing from the spirit and scope of the disclosure. For example, the effective delivery of the medicament may be optimized by manipulating the waveform of the piezoelectric vibrator. All these and other such modifications and variations are intended to be included herein within the scope of this disclosure and protected by the following claims. Therefore the scope of the disclosure is not intended to be limited except as indicated in the appended claims.
This application is a continuation in part of U.S. application Ser. No. 12/785,082, filed May 21, 2010, which claims priority from the U.S. Provisional Application Ser. No. 61/180,396, filed May 21, 2009, the contents of which are incorporated herein in their entireties, by reference.
Number | Name | Date | Kind |
---|---|---|---|
2517482 | Hall | Aug 1950 | A |
3507277 | Altounyan et al. | Apr 1970 | A |
3518992 | Altounyan et al. | Jul 1970 | A |
3635219 | Altounyan et al. | Jan 1972 | A |
3653380 | Hansen | Apr 1972 | A |
3795244 | Lax et al. | Mar 1974 | A |
3807400 | Cocozza | Apr 1974 | A |
3831606 | Damani | Aug 1974 | A |
3948264 | Wilke et al. | Apr 1976 | A |
4094317 | Wasnich | Jun 1978 | A |
4240418 | Rosskamp et al. | Dec 1980 | A |
4452239 | Malem | Jun 1984 | A |
4627432 | Newell et al. | Dec 1986 | A |
4733797 | Haber | Mar 1988 | A |
5152284 | Valentini et al. | Oct 1992 | A |
5260321 | Hof et al. | Nov 1993 | A |
5344043 | Moulding et al. | Sep 1994 | A |
5349947 | Newhouse et al. | Sep 1994 | A |
5429302 | Abbott | Jul 1995 | A |
5458135 | Patton et al. | Oct 1995 | A |
5497763 | Lloyd et al. | Mar 1996 | A |
5503869 | Van Oort | Apr 1996 | A |
5694920 | Abrams et al. | Dec 1997 | A |
5699649 | Abrams et al. | Dec 1997 | A |
5709202 | Lloyd et al. | Jan 1998 | A |
5724959 | McAughey et al. | Mar 1998 | A |
5727546 | Clarke et al. | Mar 1998 | A |
5740793 | Hodson et al. | Apr 1998 | A |
5758823 | Glezer et al. | Jun 1998 | A |
5823178 | Lloyd et al. | Oct 1998 | A |
5823434 | Cooper | Oct 1998 | A |
5884624 | Barnett et al. | Mar 1999 | A |
5894990 | Glezer et al. | Apr 1999 | A |
5906202 | Schuster et al. | May 1999 | A |
5908158 | Cheiman | Jun 1999 | A |
5938118 | Cooper | Aug 1999 | A |
6026809 | Abrams et al. | Feb 2000 | A |
6032666 | Davies et al. | Mar 2000 | A |
6142146 | Abrams et al. | Nov 2000 | A |
6152130 | Abrams et al. | Nov 2000 | A |
6209538 | Casper et al. | Apr 2001 | B1 |
6312909 | Shyjan | Nov 2001 | B1 |
6328033 | Avrahami | Dec 2001 | B1 |
6347629 | Braithwaite | Feb 2002 | B1 |
6367470 | Denyer et al. | Apr 2002 | B1 |
6415790 | Leedom et al. | Jul 2002 | B1 |
6457654 | Glezer et al. | Oct 2002 | B1 |
6536427 | Davies et al. | Mar 2003 | B2 |
6543442 | Gonda et al. | Apr 2003 | B2 |
6546927 | Litherland et al. | Apr 2003 | B2 |
6622720 | Hadimioglu | Sep 2003 | B2 |
6629646 | Ivri | Oct 2003 | B1 |
6698425 | Widerstrom | Mar 2004 | B1 |
6722581 | Saddoughi | Apr 2004 | B2 |
6759159 | Gray et al. | Jul 2004 | B1 |
6792945 | Davies et al. | Sep 2004 | B2 |
6840239 | Myrman | Jan 2005 | B2 |
6871647 | Allan et al. | Mar 2005 | B2 |
6889690 | Crowder et al. | May 2005 | B2 |
6962266 | Morgan et al. | Nov 2005 | B2 |
6971383 | Hickey et al. | Dec 2005 | B2 |
7080644 | Gumaste | Jul 2006 | B2 |
7093595 | Nesbitt | Aug 2006 | B2 |
7233228 | Lintell | Jun 2007 | B2 |
7318434 | Gumaste et al. | Jan 2008 | B2 |
7334577 | Gumaste et al. | Feb 2008 | B2 |
7451761 | Hickey et al. | Nov 2008 | B2 |
7538473 | Blandino et al. | May 2009 | B2 |
7607435 | Lipp | Oct 2009 | B2 |
7748382 | Denyer et al. | Jul 2010 | B2 |
8196576 | Kriksunov et al. | Jun 2012 | B2 |
8256416 | Houzego et al. | Sep 2012 | B2 |
8375941 | King et al. | Feb 2013 | B2 |
8763606 | Mosier et al. | Jul 2014 | B2 |
20020032409 | Ritsche | Mar 2002 | A1 |
20030041859 | Abrams et al. | Mar 2003 | A1 |
20030192540 | Myrman et al. | Oct 2003 | A1 |
20040250812 | Davies et al. | Dec 2004 | A1 |
20040263567 | Hess et al. | Dec 2004 | A1 |
20050087189 | Crockford et al. | Apr 2005 | A1 |
20050103337 | Hickey et al. | May 2005 | A1 |
20050109659 | Hickey et al. | May 2005 | A1 |
20050121027 | Nilsson et al. | Jun 2005 | A1 |
20050147566 | Fleming et al. | Jul 2005 | A1 |
20050155601 | Steiner et al. | Jul 2005 | A1 |
20050172962 | Gumaste et al. | Aug 2005 | A1 |
20050174216 | Lintell | Aug 2005 | A1 |
20050183725 | Gumaste et al. | Aug 2005 | A1 |
20050267628 | Crowder et al. | Dec 2005 | A1 |
20050268909 | Bonney et al. | Dec 2005 | A1 |
20060174869 | Gumaste et al. | Aug 2006 | A1 |
20060213503 | Borgschulte et al. | Sep 2006 | A1 |
20060257327 | Zierenberg et al. | Nov 2006 | A1 |
20070119969 | Collins et al. | May 2007 | A1 |
20070137645 | Eason et al. | Jun 2007 | A1 |
20070215149 | King et al. | Sep 2007 | A1 |
20080202514 | Kriksunov et al. | Aug 2008 | A1 |
20090020113 | Watanabe | Jan 2009 | A1 |
20090308390 | Smutney et al. | Dec 2009 | A1 |
20090314288 | Gumaste | Dec 2009 | A1 |
20100139654 | Thoemmes et al. | Jun 2010 | A1 |
20100252032 | Thoemmes et al. | Oct 2010 | A1 |
20110041844 | Dunne | Feb 2011 | A1 |
20130213392 | Mosier | Aug 2013 | A1 |
Number | Date | Country |
---|---|---|
102005005540 | Aug 2006 | DE |
102009005048 | Jul 2010 | DE |
1 499 276 | Jan 2005 | EP |
0 799 076 | Mar 2005 | EP |
1 124 602 | Apr 2005 | EP |
1 534 366 | Jun 2005 | EP |
1 617 820 | Jan 2006 | EP |
1 691 781 | Aug 2006 | EP |
1 713 530 | Oct 2006 | EP |
1 986 721 | Nov 2008 | EP |
1 581 291 | Jan 2009 | EP |
2 054 167 | May 2009 | EP |
1 292 347 | Oct 2009 | EP |
1 691 783 | Nov 2009 | EP |
2 162 174 | Mar 2010 | EP |
2 016 965 | May 2010 | EP |
2 047 881 | Aug 2010 | EP |
2 234 728 | Oct 2010 | EP |
1 706 099 | May 2011 | EP |
H10-506028 | Jun 1998 | JP |
2007-520247 | Jul 2007 | JP |
WO9606581 | Mar 1996 | WO |
WO 9726934 | Jul 1997 | WO |
WO 9832479 | Jul 1998 | WO |
WO 9964095 | Dec 1999 | WO |
WO 9965550 | Dec 1999 | WO |
WO 03092576 | Nov 2003 | WO |
WO 2004002394 | Jan 2004 | WO |
WO 2004093848 | Nov 2004 | WO |
WO 2005053646 | Jun 2005 | WO |
WO 2005074455 | Aug 2005 | WO |
WO 2007096111 | Aug 2007 | WO |
WO 2008021281 | Feb 2008 | WO |
WO 2008106616 | Sep 2008 | WO |
WO 2009007068 | Jan 2009 | WO |
WO 2009090084 | Jul 2009 | WO |
WO 2010135672 | Nov 2010 | WO |
WO 2011160932 | Dec 2011 | WO |
WO 2011163272 | Dec 2011 | WO |
Entry |
---|
Chinese Office Action issued in corresponding Chinese Patent Application Serial No. 201080022180.3, dated Jan. 14, 2013, with translation. (12 pgs). |
International Search Report and Written Opinion, Jul. 21, 2010. |
New Zealand Examination Report, Patent Appln. No. 596564, dated Oct. 2, 2012, 2 pages. |
Eurasian Office Action (w/translation) issued in related application No. 201171452, dated Nov. 1, 2013 (2 pgs). |
Chinese Third Office Action (w/translation) issued in related application No. 201080022180.3, dated Dec. 31, 2013 (14 pgs). |
Australian Patent Examination Report No. 1 issued in related application No. 2010249402, dated Jan. 10, 2014 (3 pgs). |
Office Action issued in related U.S. Appl. No. 12/785,082, dated Oct. 23, 2013 (35 pgs). |
Second Chinese Office Action issued in corresponding application No. 201080022180.3, dated Jul. 11, 2013 (9 pgs). |
Official Action and translation issued in corresponding Chilean case Appln. No. 2900-2011, dated Oct. 2, 2013 (15 pgs). |
Australian Patent Examination Report No. 2 issued in corresponding Australian Patent Serial No. 2010249402 dated Mar. 3, 2014 (3 pgs). |
Translation of Japanese Action issued in related Japanese Patent Appln. Serial No. 2012-512067 dated Feb. 27, 2014 (2 pgs). |
Japanese Decision of Refusal (with translation) issued in related application No. 2012-512067, dated Jun. 23, 2014 (4 pgs). |
Mexican Office Action (with translation) issued in related application No. MX/a/2011/012265, dated Apr. 10, 2014 (5 pgs). |
Notice of Allowance issued in related U.S. Appl. No. 12/785,082, dated May 9, 2014 (33 pgs). |
Eurasian Office Action (with translation) issued in related application No. 201171452, dated Sep. 4, 2014 (4 pgs). |
Indonesian Office Action (no translation) issued in related application No. W-00201104678, dated Oct. 2, 2014 (2 pgs). |
Number | Date | Country | |
---|---|---|---|
20130213392 A1 | Aug 2013 | US |
Number | Date | Country | |
---|---|---|---|
61180396 | May 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12785082 | May 2010 | US |
Child | 13840577 | US |